General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee, Notice of Meeting
FDA announces a public meeting of the General and Plastic Surgery Devices Panel to discuss device classification and safety, which may affect future regulations on devices used in med spas (e.g., lasers, injectables). No immediate action required.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. All med spa and aesthetics clinics using FDA-regulated devices (lasers, injectables, etc.) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Meeting date: February 25-26, 2021. No compliance deadline yet.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA will hold a public advisory committee meeting to discuss general and plastic surgery devices, potentially leading to reclassification or new safety requirements.
Who it affects
All med spa and aesthetics clinics using FDA-regulated devices (lasers, injectables, etc.)
What you must do
Monitor meeting outcomes and any subsequent FDA guidance or rulemaking; no immediate compliance action.
Deadline
Meeting date: February 25-26, 2021. No compliance deadline yet.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication